Suppr超能文献

小鼠重组白细胞介素-10在大鼠两种多微生物性腹膜炎模型中的微生物学及炎症效应

Microbiological and inflammatory effects of murine recombinant interleukin-10 in two models of polymicrobial peritonitis in rats.

作者信息

Montravers P, Maulin L, Mohler J, Carbon C

机构信息

INSERM U. 13, Hôpital Bichat, 75877 Paris Cedex, France.

出版信息

Infect Immun. 1999 Apr;67(4):1579-84. doi: 10.1128/IAI.67.4.1579-1584.1999.

Abstract

A protective effect of interleukin-10 (IL-10) against the development of lethal shock has been demonstrated in various animal models. In contrast, the immunosuppressant properties of this mediator have been minimally evaluated in low-mortality models of infections. The clinical, microbiological, and inflammatory effects of murine recombinant IL-10 (mrIL-10) therapy were evaluated in two models of peritonitis in rats, which differed in the degree of severity of peritoneal inflammation 3 days after inoculation of Escherichia coli and Bacteroides fragilis with or without Enterococcus faecalis. The severity of the disease remained unchanged compared to that in control animals. A dose-related decrease in the peritoneal phagocyte count was observed in the treated groups compared to the counts in control animals. The subsequent experiments were performed exclusively in the mixed gram-positive-gram negative model, which exhibits an intense and prolonged inflammatory response with similar criteria. The early effects of mrIL-10 (evaluated 6 h after inoculation), repeated injections of mrIL-10 (four doses injected from 0 to 9 h after bacterial challenge), and pretreatment (two doses injected 6 and 3 h before inoculation) were evaluated. The clinical and microbiological parameters remained unchanged in the treated animals. Decreases in the peritoneal phagocyte count and the peritoneal concentration of tumor necrosis factor were observed following repeated injections of mrIL-10. In summary, our data suggest that mrIL-10 does not worsen the manifestations of sepsis. However, these results need to be confirmed in clinical practice.

摘要

白细胞介素-10(IL-10)对致死性休克发展的保护作用已在多种动物模型中得到证实。相比之下,该介质的免疫抑制特性在低死亡率感染模型中评估甚少。在两种大鼠腹膜炎模型中评估了鼠重组IL-10(mrIL-10)治疗的临床、微生物学和炎症效应,这两种模型在接种大肠埃希菌和脆弱拟杆菌(有或无粪肠球菌)3天后腹膜炎症的严重程度有所不同。与对照动物相比,疾病严重程度未发生变化。与对照动物的计数相比,治疗组中观察到腹膜吞噬细胞计数呈剂量相关下降。随后的实验仅在革兰氏阳性-革兰氏阴性混合模型中进行,该模型表现出强烈且持久的炎症反应,采用类似标准。评估了mrIL-10的早期效应(接种后6小时评估)、mrIL-10的重复注射(细菌攻击后0至9小时注射四剂)以及预处理(接种前6小时和3小时注射两剂)。治疗动物的临床和微生物学参数未发生变化。重复注射mrIL-10后,观察到腹膜吞噬细胞计数和腹膜肿瘤坏死因子浓度下降。总之,我们的数据表明mrIL-10不会使脓毒症表现恶化。然而,这些结果需要在临床实践中得到证实。

相似文献

本文引用的文献

10
IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils.
Am J Physiol. 1996 Oct;271(4 Pt 1):L566-71. doi: 10.1152/ajplung.1996.271.4.L566.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验